Search

Your search keyword '"Savarino, E."' showing total 1,299 results
Start Over Author "Savarino, E."
1,299 results on '"Savarino, E."'

3. Microbiological assessment of bile in patients undergoing Endoscopic Retrograde Cholangiography: the “MICROBILE” Registry

Author

Binda, C., additional, Gibiino, G., additional, Perini, B., additional, Coluccio, C., additional, Fabbri, S., additional, Giuffrida, P., additional, Cucchetti, A., additional, Alessandro, C., additional, Lucchi, G., additional, Cristini, F., additional, Raumer, L., additional, Savarino, E., additional, Cricca, M., additional, Sambri, V., additional, and Fabbri, C., additional

Published
2024
Full Text
View/download PDF

5. Risk Stratification for BD-IPMN Malignant Transformation. The role of operative dimensional grouping in the cost-effectiveness optimization of surveillance guidelines. The PACMANS Study

Author

Kayali, S., additional, Marabotto, E., additional, Dibitetto, S., additional, Gaiani, F., additional, Busatto, A., additional, Caprioli, S., additional, Luzzi, A. P., additional, Savarino, E., additional, Laghi, L., additional, De Angelis, C., additional, and Giannini, E. G., additional

Published
2024
Full Text
View/download PDF

8. P965 Ulcerative proctitis treated with biologics: is it too hard to treat?

Author

Bertani, L, primary, Tricò, D, additional, Barberio, B, additional, Bretto, E, additional, Ceccarelli, L, additional, Calabrese, F, additional, Pasta, A, additional, Bertin, L, additional, Fabiana, Z, additional, Maniero, D, additional, Frara, S, additional, De Bernardi, A, additional, Bodini, G, additional, Ribaldone, D G, additional, Costa, F, additional, and Savarino, E V, additional

Published
2024
Full Text
View/download PDF

9. P1016 Real-world data on sequential therapy in moderate-to-severe UC: Unveiling second-line strategies after anti-TNF failure

Author

Farkas, B, primary, Borsos, M, additional, Resál, T, additional, Bacsur, P, additional, Szepes, Z, additional, Savarino, E V, additional, Bertin, L, additional, Limdi, J K, additional, Sethi-Arora, K, additional, Miheller, P, additional, Vilmos, F, additional, Castiglione, F, additional, Bonacci, L, additional, Lukas, M, additional, Maharshak, N, additional, Berman, G, additional, Krznarić, Ž, additional, Wetwittayakhlang, P, additional, Lakatos, P L, additional, Seidelin, J B, additional, Attauabi, M, additional, Michalopoulos, G, additional, Ribaldone, D G, additional, Kagramanova, A, additional, Chashkova, E, additional, Sarlós, P, additional, Saibeni, S, additional, Shitrit, A B G, additional, Molnár, T, additional, and Farkas, K, additional

Published
2024
Full Text
View/download PDF

10. P576 Fecal calprotectin could predict clinical and endoscopic response to ustekinumab therapy

Author

Bertani, L, primary, Tricò, D, additional, Barberio, B, additional, Vernero, M, additional, Bretto, E, additional, Ceccarelli, L, additional, Pardi, V, additional, Calabrese, F, additional, Pasta, A, additional, Bertin, L, additional, Fabiana, Z, additional, Semprucci, G, additional, Bodini, G, additional, Ribaldone, D G, additional, Savarino, E V, additional, and Costa, F, additional

Published
2024
Full Text
View/download PDF

13. P621 Safety and effectiveness of vedolizumab and ustekinumab in inflammatory bowel disease patients after liver transplantation for primary sclerosing cholangitis: results from an ECCO-confer case series

Author

Holvoet, T, primary, Verstockt, B, additional, Lenfant, M, additional, Julsgaard, M, additional, Drobne, D, additional, Thakor, A, additional, Gordon, H, additional, Molnar, T, additional, Savarino, E V, additional, Ribaldone, D G, additional, Miheller, P, additional, Vieujean, S, additional, Candel, I, additional, Menchen, L, additional, Bettenworth, D, additional, Eder, P, additional, Issachar, A, additional, and Lobaton, T, additional

Published
2024
Full Text
View/download PDF

14. P413 Bowel Urgency in patients with Ulcerative Colitis: prevalence and association with clinical, endoscopic data and disability

Author

Nardone, O M, primary, Calabrese, G, additional, Allocca, M, additional, Caprioli, F, additional, Fantini, M C, additional, Onali, S, additional, Orlando, A, additional, Savarino, E, additional, Soriano, A, additional, Variola, A, additional, de Sire, R, additional, La Mantia, A, additional, Testa, A, additional, and Castiglione, F, additional

Published
2024
Full Text
View/download PDF

15. DOP79 Promising efficacy of biologicals and small molecules for microscopic colitis: results from a large real-life multicenter cohort

Author

Verstockt ., B, primary, Taelman, T, additional, Vavricka, S R, additional, Zabana, Y, additional, Lenfant, M, additional, Macaigne, G, additional, Maillard, M H, additional, Savarino, E, additional, Teich, N, additional, Kiudelis, V, additional, de la Revilla Negro, J, additional, Ribaldone, D G, additional, Barreiro-de Acosta, M, additional, Wildt, S, additional, Rivière, P, additional, Fumery, M, additional, Truyens, M, additional, Amiot, A, additional, Marsal, J, additional, Levartovsky, A, additional, Vieujean, S, additional, Somers, M, additional, Cremer, A, additional, Lutakov, I, additional, Cohen, N A, additional, Dewit, S, additional, Bajer, L, additional, Rahier, J F, additional, Backman, A S, additional, Nancey, S, additional, Choden, T, additional, Van Dongen, J, additional, Münch, A, additional, and Julsgaard, M, additional

Published
2024
Full Text
View/download PDF

17. P544 Ustekinumab safety and effectiveness in ulcerative colitis patients: results from a large real-life study

Author

Mocci, G, primary, Scaldaferri, F, additional, Pugliese, D, additional, Savarino, E, additional, Bodini, G, additional, Cuomo, A, additional, Donnarumma, L, additional, Maconi, G, additional, Cataletti, G, additional, Rodino, S, additional, Sebkova, L, additional, Ferronato, A, additional, Gaiani, F, additional, Marzo, M, additional, Luppino, I, additional, Paese, P, additional, Elisei, W, additional, Monterubbianesi, R, additional, Faggiani, R, additional, Napolitano, D, additional, Grossi, L, additional, Serio, M, additional, Scarcelli, A, additional, Lorenzetti, R, additional, Allegretta, L, additional, Rocco, G, additional, Zampaletta, C, additional, Bolognini, L, additional, Meucci, C, additional, Colucci, R, additional, Tonti, P, additional, Della Valle, N, additional, Piga, R, additional, Forti, G, additional, Onidi, F M, additional, Usai Satta, P, additional, Picchio, M, additional, Papa, A, additional, and Tursi, A, additional

Published
2024
Full Text
View/download PDF

19. P908 Real-life effectiveness and safety of tofacitinib and vedolizumab as a second-line therapy in anti-TNFs experienced patients ulcerative colitis: preliminary results of an IGIBD study (VE2TO-UC)

Author

Noviello, D, primary, Savarino, E, additional, Fries, W, additional, Fantini, M C, additional, Conforti, F, additional, Orlando, A, additional, Ribaldone, D G, additional, Mocci, G, additional, Viganò, C, additional, Festa, S, additional, Spagnuolo, R, additional, Campigotto, M, additional, Grossi, L, additional, Gravina, A G, additional, Principi, M, additional, Imperatore, N, additional, Carvalhas, A, additional, Scardino, G, additional, Scaldaferri, F, additional, Ceccarelli, L, additional, Biancone, L, additional, Di Sario, A, additional, De Barba, C, additional, De Francesco, C, additional, Calderone, S, additional, Onali, S, additional, Vecchi, M, additional, Ventimiglia, M, additional, and Caprioli, F, additional

Published
2024
Full Text
View/download PDF

20. Pharmacological Management of Gastro-Esophageal Reflux Disease: An Update of the State-of-the-Art

Author

Savarino V, Marabotto E, Zentilin P, Demarzo MG, de Bortoli N, and Savarino E

Subjects
medical management of gerd, proton pump inhibitors, potassium competitive acid blockers, ppi-refractory patients, esophageal mucosal resistance, mucosal protective agents, bile acid sequestrant drug, Therapeutics. Pharmacology, RM1-950
Abstract

Vincenzo Savarino,1 Elisa Marabotto,1 Patrizia Zentilin,1 Maria Giulia Demarzo,1 Nicola de Bortoli,2 Edoardo Savarino3 1Department of Internal Medicine (DIMI), University of Genoa, Genoa, Italy; 2Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy; 3Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, ItalyCorrespondence: Vincenzo SavarinoDepartment of Internal Medicine (DIMI), University of Genoa, Genoa, ItalyEmail vsavarin@unige.itAbstract: Gastro-esophageal reflux disease (GERD) is a highly prevalent, chronic disorder, whose knowledge remains limited and the management of these patients changes continuously. This review provides a summary of the most recent advancements in the pathogenesis of this disease and the new drugs introduced into the market to overcome some of the unmet needs of traditional therapies. Nowadays, the most fruitful diagnostic examinations are 24-hour impedance-pH monitoring, which allows us to separate true NERD from esophageal functional disorders and high-resolution manometry, which helps to exclude the existence of motility disorders sharing the same symptoms of GERD. Proton pump inhibitors (PPIs) remain the first-choice therapy in the treatment of GERD, but a consistent proportion of these patients continue to experience symptoms despite their intake. These cases pertain mainly to the subpopulation with non-erosive reflux disease (NERD) and represent very challenging clinical situations, because it is mandatory to understand the reasons for PPI failure. The management of these difficult patients requires necessarily to test them and avoid the use of empiric treatments that are often unsuccessful, costly and potentially dangerous. Recently, several new drugs have been used to increase the defensive properties of this mucosa with promising results in randomized clinical trials.Keywords: medical management of GERD, proton pump inhibitors, potassium competitive acid blockers, PPI-refractory patients, esophageal mucosal resistance, mucosal protective agents, bile acid sequestrant drug

Published
2021

22. Vonoprazan Fumarate for the Treatment of Gastric Ulcers: A Short Review on Emerging Data

Author

Marabotto E, Ziola S, Savarino V, Giannini EG, Furnari M, Bodini G, Zingone F, Ghisa M, Barberio B, Zentilin P, and Savarino E

Subjects
gastric ulcer, p-cab, adverse events, peptic disease, ppi, h2-receptor antagonists, Diseases of the digestive system. Gastroenterology, RC799-869
Abstract

Elisa Marabotto, 1 Sebastiano Ziola, 1 Vincenzo Savarino, 1 Edoardo Giovanni Giannini, 1 Manuele Furnari, 1 Giorgia Bodini, 1 Fabiana Zingone, 2 Matteo Ghisa, 2 Brigida Barberio, 2 Patrizia Zentilin, 1 Edoardo Savarino 2 1Division of Gastroenterology, Department of Internal Medicine, University of Genoa, Genoa, Italy; 2Division of Gastroenterology, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, ItalyCorrespondence: Elisa MarabottoDivision of Gastroenterology, Department of Internal Medicine, University of Genoa, Viale Benedetto XV, 6, Genova 16132, ItalyTel/Fax +390103538923Email elisa.marabotto@unige.itAbstract: Potassium-competitive acid blockers (P-CABs), such as vonoprazan, represent a novel and heterogeneous class of drugs that competitively block the potassium binding site of gastric H+/K+ ATPase, thus potentially overcoming the limitations of proton-pump inhibitors. Different studies evaluated the efficacy of vonoprazan versus proton-pump inhibitors (PPIs) for the treatment of acid-related disorders, and, therefore, P-CABs present the same indications of PPIs: gastroesophageal reflux disease, gastric and duodenal ulcer healing, management of upper gastrointestinal bleeding, non-steroidal anti-inflammatory drug (NSAID)-associated ulcers and Helicobacter pylori eradication therapy. The aim of this review was to evaluate the role of vonoprazan for the treatment of peptic ulcer disease (PUD) and the management of gastric ulcer occurring after endoscopic submucosal dissection (ESD). Indeed, vonoprazan (at the dose of both 10 and 20mg) showed similar results to PPIs in patients taking long-term NSAIDs, in the absence of severe adverse effects, and provided a more rapid and effective treatment of ulcers induced by ESD. However, studies in medical literature are heterogeneous, mainly performed with a retrospective design, and often carried out in Japan only. For these reasons, further prospective, randomized studies are warranted in order to help physicians, patients, and policymakers regarding the use of vonoprazan in clinical practice.Keywords: gastric ulcer, P-CAB, adverse events, peptic disease, PPI, H2-receptor antagonists

Published
2020

23. Idiopathic pulmonary fibrosis and GERD: links and risks

Author

Ghisa M, Marinelli C, Savarino V, and Savarino E

Subjects
Idiopathic Pulmonary Fibrosis, microaspiration, chronic cough, GERD, reflux disease, motility, Therapeutics. Pharmacology, RM1-950
Abstract

Matteo Ghisa1, Carla Marinelli1, Vincenzo Savarino2, Edoardo Savarino1 1Gastrointestinal Unit, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy; 2Gastrointestinal Unit, Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, ItalyCorrespondence: Edoardo SavarinoGastrointerology Unit, Department of Surgery, Oncology and Gastroenterology, University of Padua, Via Giustiniani 2, Padova 351258, ItalyTel +39 049 821 7749Fax +39 049 876 0820Email edoardo.savarino@unipd.itAbstract: Gastroesophageal reflux disease (GERD) and idiopathic pulmonary fibrosis (IPF) are two pathological conditions often strictly related, even if a clear relationship of causality has not been demonstrated. GERD is a frequent comorbidity in IPF patients, as demonstrated using combined multichannel intraluminal impedance-pH, despite being mostly clinically silent. According to that, it has been hypothesized that microaspiration of gastric material may play a fundamental role in the fibrotic transformation of pulmonary parenchyma. In contrast, it cannot be excluded that IPF may favor GERD by increasing the negative intrathoracic pressure. Therefore, this relationship is uncertain as well as not univocal. Nevertheless, the latest international guidelines recommend the use of proton pump inhibitors (PPIs) in IPF based on several data showing that PPIs can stabilize lung function, reduce disease flares and hospitalizations. On the contrary, recent studies not only question the relevance of these results, but also associate the use of PPIs with an increased risk of lung infections and a negative prognostic outcome. The aim of this review is to analyze the possible links between GERD and IPF and their possible therapeutic implications, trying to translate this scientific evidence into useful information for clinical practice.Keywords: idiopathic pulmonary fibrosis, microaspiration, chronic cough, GERD, reflux disease, motility

Published
2019

24. Pneumocystis jirovecii Pneumonia in Patients with Inflammatory Bowel Disease–a Case Series

Author

Vieujean, S, Moens, A, Hassid, D, Rothfuss, K, Savarino, E, Vavricka, S R, Reenaers, C, Jacobsen, B, Allez, M, Ferrante, M, Rahier, Jean-François, ECCO CONFER investigators, UCL - SSS/IREC/MONT - Pôle Mont Godinne, and UCL - (MGD) Service de gastro-entérologie

Subjects
inflammatory bowel disease, Gastroenterology, General Medicine, Pneumocystis jirovecii pneumonia
Abstract

Background and aim: Pneumocystis jirovecii pneumonia [PJP] is a very rare, potentially life-threatening pulmonary fungal infection that occurs in immunocompromised individuals including patients with inflammatory bowel disease [IBD]. Our aim was to describe immunosuppressive treatment exposure as well as the outcome in IBD patients with PJP.Methods: PJP cases were retrospectively collected through the COllaborative Network For Exceptionally Rare case reports of the European Crohn's and Colitis Organisation. Clinical data were provided through a case report form.Results: In all, 18 PJP episodes were reported in 17 IBD patients [10 ulcerative colitis and seven Crohn's disease]. The median age at PJP diagnosis was 55 years (interquartile range [IQR], 40-68 years]. Two PJP [11.1%] occurred in patients on triple immunosuppression, 10 patients [55.6%] had double immunosuppressive treatment, four patients [22.2%] had monotherapy and two PJP occurred in absence of immunosuppressive treatment [one in a human immunodeficiency virus patient and one in a patient with a history of autologous stem cell transplantation]. Immunosuppressive therapies included steroids [n = 12], thiopurines [n = 10], infliximab [n = 4], ciclosporin [n = 2], methotrexate [n = 1], and tacrolimus [n = 1]. None of the patients diagnosed with PJP had received prophylaxis. All patients were treated by trimethoprim/sulphamethoxazole or atovaquone and an intensive care unit [ICU] stay was required in seven cases. Two patients [aged 71 and 32 years] died, and one patient had a recurrent episode 16 months after initial treatment. Evolution was favourable for the others.Conclusion: This case series reporting potentially fatal PJP highlights the need for adjusted prophylactic therapy in patients with IBD on immunosuppressive therapy. Background and aim: Pneumocystis jirovecii pneumonia [PJP] is a very rare, potentially life-threatening pulmonary fungal infection that occurs in immunocompromised individuals including patients with inflammatory bowel disease [IBD]. Our aim was to describe immunosuppressive treatment exposure as well as the outcome in IBD patients with PJP.Methods: PJP cases were retrospectively collected through the COllaborative Network For Exceptionally Rare case reports of the European Crohn's and Colitis Organisation. Clinical data were provided through a case report form.Results: In all, 18 PJP episodes were reported in 17 IBD patients [10 ulcerative colitis and seven Crohn's disease]. The median age at PJP diagnosis was 55 years (interquartile range [IQR], 40-68 years]. Two PJP [11.1%] occurred in patients on triple immunosuppression, 10 patients [55.6%] had double immunosuppressive treatment, four patients [22.2%] had monotherapy and two PJP occurred in absence of immunosuppressive treatment [one in a human immunodeficiency virus patient and one in a patient with a history of autologous stem cell transplantation]. Immunosuppressive therapies included steroids [n = 12], thiopurines [n = 10], infliximab [n = 4], ciclosporin [n = 2], methotrexate [n = 1], and tacrolimus [n = 1]. None of the patients diagnosed with PJP had received prophylaxis. All patients were treated by trimethoprim/sulphamethoxazole or atovaquone and an intensive care unit [ICU] stay was required in seven cases. Two patients [aged 71 and 32 years] died, and one patient had a recurrent episode 16 months after initial treatment. Evolution was favourable for the others.Conclusion: This case series reporting potentially fatal PJP highlights the need for adjusted prophylactic therapy in patients with IBD on immunosuppressive therapy.

Published
2022

28. T.05.3 BASELINE ANXIETY SCORES PREDICT ESCALATION TO HIGHER DOSES OF PAROXETINE IN PATIENTS WITH FUNCTIONAL HEARTBURN AND REFLUX HYPERSENSITIVITY

Author

Baiano Svizzero, F., primary, Visaggi, P., additional, Venturini, A., additional, Stefani Donati, D., additional, Mariani, L., additional, Rosi, E.M., additional, Ovidi, F., additional, Adamo, G., additional, Cacciatore, M., additional, Bellini, M., additional, Savarino, E., additional, and De Bortoli, N., additional

Published
2023
Full Text
View/download PDF

36. T.06.8 REAL WORD LONG-TERM EFFICACY AND SAFETY OF VEDOLIZUMAB IN MANAGING ULCERATIVE COLITIS VERSUS CROHN'S DISEASE: RESULTS FROM “LONG VEDO” ITALIAN MULTICENTER STUDY

Author

Mocci, G., primary, Maconi, G., additional, Cataletti, G., additional, Mantia, B., additional, Serio, M., additional, Scarcelli, A., additional, Onidi, F.M., additional, Pagnini, C., additional, Graziani, M., additional, Di Paolo, M., additional, Pranzo, G., additional, Luppino, I., additional, Paese, P., additional, Monterubbianesi, R., additional, Faggiani, R., additional, Ferronato, A., additional, Perini, B., additional, Savarino, E., additional, Binaghi, L., additional, Schiavoni, E., additional, Napolitano, D., additional, Scaldaferri, F., additional, Papa, A., additional, Lorenzetti, R., additional, Pica, R., additional, Cocco, A., additional, Rodino, S., additional, Sebkova, L., additional, Zampaletta, C., additional, Gaiani, F., additional, Fanigliulo, L., additional, Allegretta, L., additional, Cuomo, A., additional, Donnarumma, L., additional, Della Valle, N., additional, Forti, G., additional, Dore, M., additional, Antonelli, E., additional, Bassotti, G., additional, Iannelli, C., additional, Aragona, G., additional, Lauria, A., additional, Piergallini, S., additional, Colucci, R., additional, Meucci, C., additional, Usai Satta, P., additional, Elisai, W., additional, and Tursi, A., additional

Published
2023
Full Text
View/download PDF

39. P778 Effectiveness and safety of a second-line rescue therapy for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study)

Author

García, M J, primary, Riestra, S, additional, Amiot, A, additional, Julsgaard, M, additional, García de la Filia, I, additional, Calafat, M, additional, Aguas, M, additional, de la Peña, L, additional, Roig-Ramos, C, additional, Caballol, B, additional, Casanova, M J, additional, Farkas, K, additional, Boysen, T, additional, Bujanda, L, additional, Cuarán, C, additional, Dobru, D, additional, Fousekis, F, additional, Gargallo-Puyuelo, C J, additional, Savarino, E, additional, Calvet, X, additional, Huguet, J M, additional, Kupcinskas, L, additional, López-Cardona, J, additional, Raine, T, additional, van Oostrom, J, additional, Gisbert, J P, additional, and Chaparro, M, additional

Published
2023
Full Text
View/download PDF

40. P605 Real life efficacy of tofacitinib in different situation in ulcerative colitis: a retrospective worldwide multicentre collaborative study

Author

Resál, T, primary, Bacsur, P, additional, Bor, R, additional, Bálint, A, additional, Katsanos, K, additional, Michalopoylos, G, additional, Ribaldone, D G, additional, Attauabi, M, additional, Mirabella, Z, additional, Yanai, H, additional, Bezzio, C, additional, Castiglione, F, additional, Bar-Gil Shitrit, A, additional, Pugliese, D, additional, Lakatos, P L, additional, Savarino, E, additional, Lukáš, M, additional, Franko, M, additional, Chashkova, E, additional, Molander, P, additional, Nancey, S, additional, Bannon, L, additional, Krznaric, Z, additional, Filip, R, additional, Szamosi, T, additional, Kaštylová, K, additional, Sarlós, P, additional, Ami-Barak, H, additional, Rispo, A, additional, Limdi, J, additional, Kagramanova, A, additional, Szepes, Z, additional, Farkas, K, additional, and Molnár, T, additional

Published
2023
Full Text
View/download PDF

41. P252 Solid organ transplant (with the exception of liver) in patients with inflammatory bowel disease: An ECCO CONFER Multicentre Case Series

Author

Ribaldone, D G, primary, Vieujean, S, additional, Julsgaard, M, additional, Zingone, F, additional, Savarino, E, additional, Cañete, F, additional, Aratari, A, additional, Imperatore, N, additional, Ramos, L, additional, Plaza, R, additional, Pugliese, D, additional, Barberio, B, additional, Drobne, D, additional, and Chaparro, M, additional

Published
2023
Full Text
View/download PDF

42. P674 Ustekinumab is the preferred biological agent in IBD patients with hidradenitis suppurativa failing anti-TNF therapy : results from a real-life multicenter cohort

Author

Verstockt ., B, primary, Vieujean, S, additional, Truyens, M, additional, Julsgaard, M, additional, Pugliese, D, additional, Aslan, D, additional, Prokopic, M, additional, Lim, S, additional, Viganò, C, additional, Festa, S, additional, Ramos, L, additional, Garciá, M J, additional, Plaza, R, additional, Noviello, D, additional, Savarino, E, additional, Drobne, D, additional, Imperatore, N, additional, Ribaldone, D G, additional, Van Dongen, J, additional, Teich, N, additional, Wahed, M, additional, Barberio, B, additional, and Goren, I, additional

Published
2023
Full Text
View/download PDF

43. P505 Real word long-term efficacy and safety of vedolizumab in managing ulcerative colitis versus crohn’s disease: results from “long vedo” italian multicenter study

Author

Mocci, G, primary, Maconi, G, additional, Onidi, F M, additional, Cataletti, G, additional, Elisei, W, additional, Scaldaferri, F, additional, Lorenzetti, R, additional, Pagnini, C, additional, Scarcelli, A, additional, Graziani, M G, additional, Di Paolo, M C, additional, Pranzo, G, additional, Luppino, I, additional, Monterubbianesi, R, additional, Faggiani, R, additional, Ferronato, A, additional, Savarino, E, additional, Pica, R, additional, Cocco, A, additional, Rodino, S, additional, Sebkova, L, additional, Zampaletta, C, additional, Gaiani, F, additional, Fanigliulo, L, additional, Allegretta, L, additional, Cuomo, A, additional, Donnarumma, L, additional, Della Valle, N, additional, Forti, G, additional, Antonelli, E, additional, Bassotti, G, additional, Iannelli, C, additional, Aragona, G, additional, Lauria, A, additional, Piergallini, S, additional, Colucci, R, additional, Binaghi, L, additional, Meucci, C, additional, Papa, A, additional, and Tursi, A, additional

Published
2023
Full Text
View/download PDF

44. P455 Comparison of two strategies for the management of post-operative recurrence in Crohn’s disease patients with one clinical risk factor: a multicentre IG-IBD study

Author

Dragoni, G, primary, Castiglione, F, additional, Bezzio, C, additional, Pugliese, D, additional, Spagnuolo, R, additional, Viola, A, additional, Cocomazzi, F, additional, Aratari, A, additional, Savarino, E V, additional, Balestrieri, P, additional, Onali, S, additional, Viganò, C, additional, Ribaldone, D G, additional, Innocenti, T, additional, Testa, A, additional, Saibeni, S, additional, Privitera, G, additional, Milla, M, additional, Armuzzi, A, additional, Fantini, M C, additional, and Fiorino, G, additional

Published
2023
Full Text
View/download PDF

47. Six-food elimination diet is less effective during pollen season in adults with eosinophilic esophagitis sensitized to pollens

Author

Visaggi P., Savarino E., Del Corso G., Hunter H., Baiano Svizzero F., Till S. J., Jason D., Wong T., De Bortoli N., and Zeki S.

Subjects
Biomedical statistics, SFED, Skin prick test, Eosinophilic esophagitis, EoE, Pollen allergy
Abstract

The role of inhaled and swallowed aeroallergens in treatment outcomes of adult patients with eosinophilic esophagitis (EoE) is unclear. We hypothesized that the pollen season contributes to the failure of the 6-food elimination diet (SFED) in EoE. We compared outcomes of patients with EoE who underwent SFED during vs outside of the pollen season. Consecutive adult patients with EoE who underwent SFED and skin prick test (SPT) for birch and grass pollen were included. Individual pollen sensitization and pollen count data were analyzed to define whether each patient had been assessed during or outside of the pollen season after SFED. All patients had active EoE (>=15 eosinophils/high-power field) before SFED and adhered to the diet under the supervision of a dietitian. Fifty-eight patients were included, 62.0% had positive SPT for birch and/or grass, whereas 37.9% had negative SPT. Overall, SFED response was 56.9% (95% confidence interval, 44.1%-68.8%). When stratifying response according to whether the assessment had been performed during or outside of the pollen season, patients sensitized to pollens showed significantly lower response to SFED during compared with outside of the pollen season (21.4% vs 77.3%; P = 0.003). In addition, during the pollen season, patients with pollen sensitization had significantly lower response to SFED compared with those without sensitization (21.4% vs 77.8%; P = 0.01). Pollens may have a role in sustaining esophageal eosinophilia in sensitized adults with EoE despite avoidance of trigger foods. The SPT for pollens may identify patients less likely to respond to the diet during the pollen season.

Published
2023

48. Classification of esophageal motor findings in gastro‐esophageal reflux disease: Conclusions from an international consensus group

Author

Gyawali, C. P., Roman, S., Bredenoord, A. J., Fox, M., Keller, J., Pandolfino, J. E., Sifrim, D., Tatum, R., Yadlapati, R., Savarino, E., Azpiroz, Fernando, Babaei, Arash, Bhatia, Shobna, Boeckxstaens, Guy, Bor, Serhat, Carlson, Dustin, Castell, Donald, Cicala, Michele, Clarke, John, De Bortoli, Nicola, Drug, Vasile, Frazzoni, Marzio, Holloway, Richard, Kahrilas, Peter, Kandulski, Arne, Katz, Phil, Katzka, David, Mittal, Ravinder, Mion, Francois, Novais, Luis, Patel, Amit, Penagini, Roberto, Ribolsi, Mentore, Richter, Joel, Salvador, Renato, Savarino, Vincenzo, Serra, Jordi, Schnoll‐Sussman, Felice, Smout, Andre, Soffer, Edy, Sweis, Rami, Tack, Jan, Tolone, Salvatore, Tutuian, Radu, Vaezi, Michael, Vela, Marcelo, Woodland, Philip, Wu, Justin, Xiao, Yinglian, and Zerbib, Frank

Published
2017
Full Text
View/download PDF

50. Ambulatory reflux monitoring for diagnosis of gastro‐esophageal reflux disease: Update of the Porto consensus and recommendations from an international consensus group

Author

Roman, S., Gyawali, C. P., Savarino, E., Yadlapati, R., Zerbib, F., Wu, J., Vela, M., Tutuian, R., Tatum, R., Sifrim, D., Keller, J., Fox, M., Pandolfino, J. E., Bredenoord, A. J., Azpiroz, Fernando, Babaei, Arash, Bhatia, Shobna, Boeckxstaens, Guy, Bor, Serhat, Carlson, Dustin, Castell, Donald, Cicala, Michele, Clarke, John, De Bortoli, Nicola, Drug, Vasile, Frazzoni, Marzio, Holloway, Richard, Kahrilas, Peter, Kandulski, Arne, Katz, Phil, Katzka, David, Mittal, Ravinder, Mion, Francois, Novais, Luis, Patel, Amit, Penagini, Roberto, Ribolsi, Mentore, Richter, Joel, Salvador, Renato, Savarino, Vincenzo, Serra, Jordi, Schnoll‐Sussman, Felice, Smout, Andre, Soffer, Edy, Sweis, Rami, Tack, Jan, Tolone, Salvatore, Vaezi, Michael, Woodland, Philip, and Xiao, Yinglian

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results